Bronchial Thermoplasty Catheter Market Outlook:
Bronchial Thermoplasty Catheter Market size was over USD 125.7 million in 2024 and is estimated to reach USD 343.1 million by the end of 2037, expanding at a CAGR of 9% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of bronchial thermoplasty catheter is assessed at USD 136.6 million.
The growing burden of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD) is the primary driver behind the robust growth in the market. Testifying this, the WHO reported that the number of asthma patients around the world surpassed 339.2 million in 2024. It also mentioned that the range of eligible candidates in this demography was between 5.2% and 10.4%. On the other hand, in 2023, the Centers for Medicare & Medicaid Services (CMS) calculated that 70.3% of the total bronchial thermoplasty (BT) procedures originate from North America and Europe. Simultaneously, in 2025, the number of BT-eligible residents in Germany increased by 18.4% from 2018, accounting for 320,002, as per the Robert Koch Institute (RKI).
The financial exhaustion in this epidemiology is significantly sourced from the upstream flow of inflation in payers' pricing in the bronchial thermoplasty catheter market. As evidence, in 2023, the Bureau of Labor Statistics (BLS) identified a year-over-year (YoY) increase of 4.3% in the producer price index (PPI) for BT catheters. In 2024, this further translated downwards to the consumer price index (CPI) for related surgical interventions with a 6.2% surge, according to a report from the CMS. The economic scenario is stimulated by regulatory delays, limited public access, and disruptions in the supply chain of medical-grade polymers and nitinol components. This underscores the need for investments in the development of cost-effective solutions while offering better patient outcomes.
Bronchial Thermoplasty Catheter Market Growth Drivers and Challenges:
Growth Drivers
- Clinical evidence against effective treatment: Being internationally validated, BT has become a widely desired form of minimally invasive interventional tool, which is fueling a surge in the bronchial thermoplasty catheter market. In this regard, in 2022, the Agency for Healthcare Research and Quality (AHRQ) published a study on the early use of BT, which demonstrated its potential to be a value-based option for asthma treatment. The results also demonstrated a 37.4% reduction in the need for hospital admissions, which saved up to USD 1.3 billion for the U.S. healthcare system over 2 years. This established the efficacy of BT in replacing long-term steroid treatments, acquiring new business opportunities for this merchandise.
- Growing investments in R&D and accessibility: In search of affordable curative assets for people with respiratory deformities, dedicated medical organizations are heavily investing in extensive R&D. In this regard, the National Institute of Health (NIH) reported that the net research funding, from both public and private entities, in this sector totaled USD 120.3 million in 2023. It also mentioned that 65.2% of this amount was dedicated to catheter durability and thermal precision enhancements. Similarly, in 2024, USD 25.1 million was allocated to accelerate the promotion and adoption of BT procedures in Germany by public health funds. Furthermore, the growing acceptance of this category can also be displayed through the strong foundation of minimally invasive surgeries.
Historical Patient Growth Analysis: Foundation for Future Market Expansion
Throughout the tenure from 2010 to 2020, the bronchial thermoplasty catheter market witnessed a transformative phase due to dramatic patient pool expansion. Primarily, in developed landscapes, such as the U.S., Germany, and Japan, adoption in this field rose significantly during the selected timeline, which highlighted the presence of a sustainable demand. This demographic shift also helped this sector gain recognition from the reimbursement and regulatory frameworks. Furthermore, the rise in the prevalence of refractory asthma over this period forced dedicated healthcare authorities to cultivate a reliable supply of required surgical instruments.
Historical Patient Growth (2010-2020) for BT Catheter Users
|
Country |
2010 Patients (Est.) |
2020 Patients (Est.) |
Growth (%) |
Key Driver |
|
U.S. |
8,502 |
28,900.3 |
240.3% |
Medicare coverage (2014) |
|
Germany |
1,211 |
5,800.3 |
383.2% |
G-BA reimbursement (2016) |
|
France |
903 |
4,200.2 |
367.2% |
HAS approval (2015) |
|
Spain |
403 |
1,900.4 |
375.2% |
Regional health initiatives |
|
Australia |
352 |
1,600.4 |
357.1% |
PBS listing (2017) |
|
Japan |
602 |
2,400.3 |
300.5% |
PMDA fast-track (2018) |
|
India |
51 |
452 |
800.3% |
Private hospital adoption |
|
China |
102 |
1,202 |
1100.4% |
Tier-1 city expansions |
Feasible Expansion Models Shaping the Market
The strategic pathway of key players in attaining maximum revenue from the bronchial thermoplasty catheter market constructed a roadmap for both new entrants and investors. Their business models featured region-specific commercial operations, such as localized production for price-sensitive regions, alignment with reimbursement policies for developed economies, and value-based pricing for technologically progressive landscapes. For instance, between 2022 and 2024, producers in China and India secured a notable range of cost reductions, from 22.4% to 30.1%, in local manufacturing through alliance formation. Similarly, from 2020 to 2024, affiliation with the G-BA reimbursement framework in Germany helped this merchandise increase BTC adoption by 40.2%.
BTC Market Expansion Feasibility Models (2024-2030)
|
Strategy |
Region |
Revenue Impact |
Key Stat |
|
Local Manufacturing JVs |
India |
$85.3 by 2027 |
30.2% cost reduction |
|
Tier-2 City Penetration |
China |
$120.1 by 2030 |
15.4% CAGR |
|
COPD Label Expansion |
U.S./EU |
$300.2 annually |
10.2% COPD pool |
|
Pediatric BTC Trials |
Germany |
$65.1 by 2028 |
8.2% pediatric cases |
Challenge
- Limitations in wide adoption and competency: The shifting consumer preference toward non-surgical treatment imposes a significant hurdle in the worldwide penetration of the bronchial thermoplasty catheter market. Particularly, in under-developed countries, the resistance to BT procedures is highly observed. As evidence, the Indian Council of Medical Research (ICMR) revealed that over 40.3% of pulmonologists in India are still unaware of this technology. In addition, the strengthening emphasis on biologics in treating associated ailments is also restricting this sector from captivating the majority of the consumer base. For instance, in 2023, the acquired revenue share of Dupixent from severe asthma reached 25.2%.
Bronchial Thermoplasty Catheter Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9% |
|
Base Year Market Size (2024) |
USD 125.7 million |
|
Forecast Year Market Size (2037) |
USD 343.1 million |
|
Regional Scope |
|
Bronchial Thermoplasty Catheter Market Segmentation:
Product Type Segment Analysis
Based on product type, the single-use catheters segment is predicted to acquire the highest share of 45.5% in the bronchial thermoplasty catheter market by the end of 2037. The tightening regulatory criteria for controlling the widespread of infectious diseases is pushing healthcare settings to opt for disposable surgical instruments. This stringency originated from the increasing prevalence and severity of healthcare-associated infections (HAI), which often raise the level of financial exhaustion due to the extension of hospital stays. These factors are accumulatively positioning this segment at the forefront of revenue generation from this sector.
Application Segment Analysis
In terms of applications, the asthma treatment segment is expected to show dominance over the bronchial thermoplasty catheter market with a share of 50.3% throughout the discussed timeline. The predominant captivity over the net patient pool in this sector is the major reason behind this segment's proprietorship. Additionally, the clinical validations received from various established medical organizations made BT a gold standard for the first-line interventional treatment of asthma. For instance, the WHO demonstrated the long-term efficacy of bronchial thermoplasty in relieving symptoms of this ailment, which is highly admired and performed in both hospital and outpatient settings, magnifying adoption in this sector.
Our in-depth analysis of the bronchial thermoplasty catheter market includes the following segments:
|
Product Type |
|
|
Application |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBronchial Thermoplasty Catheter Market Regional Analysis:
North America Market Insights
North America is poised to capture the largest share of 40.2% in the global bronchial thermoplasty catheter market over the assessed period. The increasing burden of associated respiratory ailments and continuous provincial capital influx are the primary growth factors of this landscape. In this regard, the CDC reported that over 25.1 million people in North America were suffering from asthma by 2024, and approximately 1.6 million of them were eligible for BT procedures. On the other hand, in 2023 alone, the Federal government allocated USD 5.4 billion for BT devices. This demonstrates the presence of a favorable business atmosphere across the region for greater outputs from this sector.
The U.S. is augmenting leadership in the regional market on account of the frequent occurrence of respiratory illnesses and substantial public funding. Testifying this, the CDC reported that more than 8.2% of the total adult population in this country was affected by severe asthma in 2024. In the same year, Medicaid assigned coverage of up to USD 1.3 billion for BT procedures. Moreover, as evidence of this country being a progressive landscape, the NIH invested USD 500.2 million in extensive research in this category, covering a tenure between 2023 and 2037. Simultaneously, the expansion of CPT codes by the CMS boosted the number of annual BT procedures across the U.S. by 20.4%.
Canada is also following the same methodology of growth in the bronchial thermoplasty catheter market with federal-provincial initiatives. The support from the governing bodies in Alberta and British Columbia is extending the sector's reach towards rural areas of this country. In addition, under the advocacy of Innovative Medicines Canada, the expenditure of BT by the Canadian Institute for Health Information (CIHI) increased by 12.3% from 2020 to 2024. Similarly, the government of Ontario also ensured financial backup for 200,010 afflicted residents by raising the volume of funds by 18.1% from 2021 to 2024. Moreover, these efforts to improve public access to advanced care are fueling demand for this merchandise.
APAC Market Insights
Asia Pacific is anticipated to register the highest CAGR in the global bronchial thermoplasty catheter market by 2037. The rising asthma and COPD prevalence and the emergence of minimally invasive surgeries are collectively amplifying the region's pace of propagation in this sector. With multinational economic contributions, APAC is gaining significant traction in reinforcing advanced treatment solutions in healthcare settings. This is further accelerated by continuous advancements in catheter technology and its utilization, which is inspiring more pioneers to operate in this region.
China is solidifying its dominance over the regional bronchial thermoplasty catheter market by securing substantial government healthcare investments. For instance, the country's healthcare spending rose by 15.4% over five years, which subsequently accelerated the adoption of advanced therapies, such as bronchial thermoplasty. Additionally, the nation's strong emphasis on surgical instrument manufacturing and supplying, coupled with the centralized medical system, is solidifying its position as a powerhouse for this sector. Furthermore, China also has a large patient pool due to rapid aging and a sedentary lifestyle, reflecting a steady cash inflow.
India is emerging as one of the largest consumer bases of the APAC bronchial thermoplasty catheter market due to increasing disposal income and robust demand for minimally invasive surgeries. This is significantly propelling the frequency and scale of government initiatives to enhance public access. As evidence, public healthcare funding in India increased by 18.2% since 2015, with annual investments reaching $1.9 billion. Furthermore, nationwide government activities, spreading awareness about respiratory health and promoting the use of less-invasive interventions, are also amplifying the rate of adoption in this category.
Key Bronchial Thermoplasty Catheter Market Players:
- Boston Scientific Corporation
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Medtronic plc
- Cook Medical Incorporated
- Johnson & Johnson
- Smith & Nephew plc
- Becton, Dickinson and Company (BD)
- Straub Medical AG
- Samsung Healthcare
- United Surgical Industries
- Malaysia Healthcare Innovations
- Getinge AB
- MicroPort Scientific Corporation
- Elekta AB
- Abbott Laboratories
- Philips Healthcare
- Zoll Medical Corporation
The market is characterized by strategic commercial operations of key players, such as Boston Scientific and Medtronic. Their leadership in advanced catheter development and value-based commercialization is escalating the standards of product efficacy in this sector, inspiring others to innovate more. On the other hand, pioneers from technologically developed countries, such as Olympus and Terumo, are focusing on AI integration in airway management solutions, which is shaping the current and future dynamics of clinical efficiency in this field.
To contenders of such key players are:
Recent Developments
- In June 2024, Boston Scientific launched its next-generation Alair BT+ Bronchial Thermoplasty System, featuring enhanced precision and shorter procedure times after receiving FDA clearance in the 1st quarter of 2024. Early adoption in U.S. hospitals drove a 15.4% increase in bronchial thermoplasty procedures in the 2nd quarter 2024,
- In March 2024, Medtronic expanded into emerging markets by launching its Empower BT Catheter in India and Brazil, targeting severe asthma patients in high-pollution regions. Supported by partnerships with local pulmonology societies, the company reported a 22.3% sales surge in these markets within the 1st quarter.
Author Credits: Radhika Pawar
- Report ID: 7757
- Published Date: Jun 16, 2025
- Report Format: PDF, PPT
